MLANA and metastatic melanoma: In a phase 1/2 clinical trial, a three-dose vaccine strategy using autologous DCs transduced with an adenoviral vector encoding the MART-1 antigen for metastatic melanoma patients showed that at least half of the treated patients had significant MART-1–specific T cell responses (Butterfield et al., 2008).